Ceftriaxone
- Generic Name
- Ceftriaxone
- Brand Names
- Rocephin
- Drug Type
- Small Molecule
- Chemical Formula
- C18H18N8O7S3
- CAS Number
- 73384-59-5
- Unique Ingredient Identifier
- 75J73V1629
Overview
Ceftriaxone is a broad-spectrum third-generation cephalosporin antibiotic. It has a very long half-life compared to other cephalosporins and is high penetrable into the meninges, eyes, and inner ear. Ceftriaxone has broader and stronger gram-negative coverage then first or second-generation cephalosporins, but worse activity against methicillin-susceptible S.aureus. Ceftriaxone is a commonly used antimicrobial due to its good activity against multi-drug resistant Enterobacteriaceae, its relatively safe adverse effect profile, and its long half-life which allows for the convenience of daily or twice-daily dosing.
Background
Ceftriaxone is a broad-spectrum third-generation cephalosporin antibiotic. It has a very long half-life compared to other cephalosporins and is high penetrable into the meninges, eyes, and inner ear. Ceftriaxone has broader and stronger gram-negative coverage then first or second-generation cephalosporins, but worse activity against methicillin-susceptible S.aureus. Ceftriaxone is a commonly used antimicrobial due to its good activity against multi-drug resistant Enterobacteriaceae, its relatively safe adverse effect profile, and its long half-life which allows for the convenience of daily or twice-daily dosing.
Indication
Ceftriaxone is used for the treatment of the infections (respiratory, skin, soft tissue, UTI, ENT) caused by susceptible organisms. Organisms that are generally susceptible to ceftriaxone include S. pneumoniae, S. pyogenes (group A beta-hemolytic streptococci), coagulase-negative staphylococci, Some Enterobacter spp, H. influenzae, N. gonorrhoeae, P. mirabilis, E. coli, Klebsiella spp, M. catarrhalis, B. burgdorferi, and some oral anaerobes.
Associated Conditions
- Abscess Brain
- Bacterial Endocarditis
- Bacterial Infections
- Bacterial Sinusitis
- Bone and Joint Infections
- Chancroid
- Community Acquired Pneumonia (CAP)
- Conjunctivitis gonococcal neonatal
- Epididymitis
- Epiglottitis
- Gonococcal arthritis
- Gonococcal infection of pharynx
- Gonococcal pelvic inflammatory disease
- Intraabdominal Infections
- Lower respiratory tract infection bacterial
- Lyme Neuroborreliosis
- Meningitis, Bacterial
- Ophthalmia neonatorum due to gonococcus
- Postoperative Infections
- Prosthetic Joint Infections
- Sepsis Bacterial
- Septic Arthritis
- Shigellosis
- Skin and Subcutaneous Tissue Bacterial Infections
- Syphilis
- Vulvovaginitis gonococcal
- Whipple Disease
- Bacterial otitis media
- Complicated Urinary Tract Infection caused by susceptible bacteria
- Disease caused by Salmonella typhi
- Susceptible Bacterial Infections
- Uncomplicated Gonorrhea
- Uncomplicated Urinary tract infection bacterial
Clinical Trials
Title | Posted | Study ID | Phase | Status | Sponsor |
|---|---|---|---|---|---|
2025/02/17 | N/A | Not yet recruiting | Ahmed Mohammed Hussein Sayed | ||
2025/01/21 | Phase 1 | Not yet recruiting | |||
2024/09/24 | Early Phase 1 | Recruiting | State University of New York - Upstate Medical University | ||
2024/08/01 | Not Applicable | Not yet recruiting | |||
2024/07/30 | Phase 2 | Not yet recruiting | |||
2024/07/10 | Phase 4 | Recruiting | |||
2024/05/02 | Phase 4 | Recruiting | |||
2024/04/05 | Phase 4 | Not yet recruiting | |||
2024/01/24 | Phase 4 | Not yet recruiting | Sichuan Provincial People's Hospital | ||
2023/08/08 | Phase 4 | Recruiting |
FDA Approved Products
Product Name | Manufacturer | Route | Strength | Approved | NDC Code |
|---|---|---|---|---|---|
Ampicillin and Sulbactam | INTRAVENOUS | 50 mg in 1 mL | 2023/04/05 | 55150-118 | |
AMPICILLIN and SULBACTAM | INTRAVENOUS, INTRAMUSCULAR | 0.5 g in 1 1 | 2022/01/21 | 67850-130 | |
UNASYN | Roerig | INTRAMUSCULAR, INTRAVENOUS | 1 g in 1 1 | 2023/03/29 | 0049-0014 |
Ampicillin and Sulbactam | INTRAVENOUS | 1 g in 1 1 | 2018/05/21 | 0409-2987 | |
Ampicillin and Sulbactam | INTRAVENOUS, INTRAMUSCULAR | 0.5 g in 1 1 | 2024/02/09 | 71288-005 | |
Ceftriaxone | INTRAVENOUS, INTRAMUSCULAR | 2 g in 1 1 | 2023/10/24 | 44567-702 | |
Ampicillin and Sulbactam | INTRAVENOUS | 5 g in 1 1 | 2024/02/09 | 71288-007 | |
Ampicillin and Sulbactam | INTRAVENOUS | 1 g in 3 g | 2018/09/17 | 0641-6120 | |
Ceftriaxone | INTRAVENOUS | 10 g in 1 1 | 2022/04/07 | 70594-098 | |
Ceftriaxone | Proficient Rx LP | INTRAVENOUS, INTRAMUSCULAR | 2 g in 1 1 | 2022/11/01 | 71205-593 |
EMA Approved Products
Medicine Name | EMA Number | Auth. Holder | Country | Drug Type | Status | Issued | Opinion | Revision |
|---|
No EMA products found
No EMA products found for this drug
Singapore Approved Products
Product Name | Manufacturer | Dosage Form | Strength | Approved | Approval No. | Online |
|---|---|---|---|---|---|---|
ROCEPHIN FOR INJECTION 1 g/vial (INTRAMUSCULAR) | F HOFFMANN-LA ROCHE LTD, Siegfried Hameln GmbH (Solvent only) | INJECTION, POWDER, FOR SOLUTION | 1 g/vial | 1988/04/27 | SIN00388P | Yes |
CEFTRIAXONE-AFT POWDER FOR INJECTION 2G/VIAL | INJECTION, POWDER, FOR SOLUTION | 2g/vial | 2017/04/11 | SIN15208P | Yes | |
MEDAXONE POWDER FOR SOLUTION FOR INJECTION OR INFUSION 1 G/VIAL | INJECTION, POWDER, FOR SOLUTION | 1000.0mg | 2021/07/26 | SIN16289P | Yes | |
CEFTRIAXONE KABI POWDER FOR SOLUTION FOR INJECTION 1G/VIAL | INJECTION, POWDER, FOR SOLUTION | 1000mg/ vial | 2016/05/20 | SIN15008P | Yes | |
TREXOFIN FOR INJECTION 2 g/vial | INJECTION, POWDER, FOR SOLUTION | 2 g/vial | 1999/07/21 | SIN11037P | Yes | |
MEDAXONE POWDER FOR SOLUTION FOR INJECTION OR INFUSION 2 G/VIAL | INJECTION, POWDER, FOR SOLUTION | 2000.0mg | 2021/07/26 | SIN16288P | Yes | |
Ceftriaxone ADVAGEN powder for solution for injection 2g/vial | INJECTION, POWDER, FOR SOLUTION | 2g/vial | 2023/07/18 | SIN16822P | Yes | |
CEFTRIAXONE-AFT POWDER FOR INJECTION 0.5G/VIAL | INJECTION, POWDER, FOR SOLUTION | 0.5g/vial | 2017/04/11 | SIN15207P | Yes | |
TRIAXONE INJECTION 2 g/vial | INJECTION, POWDER, FOR SOLUTION | 2 g/vial | 2002/11/30 | SIN12134P | Yes | |
CEFAXONE FOR INJECTION 500 mg/vial | SHIN POONG PHARMACEUTICAL CO LTD | INJECTION, POWDER, FOR SOLUTION | 500 mg/vial | 1999/04/23 | SIN10888P | Yes |
China Approved Products
Product Name | Approval No. | Manufacturer | Dosage Form | Trade Name | Strength | Type | Status | Date | Import |
|---|---|---|---|---|---|---|---|---|---|
Ceftriaxone Sodium for Injection and Sodium Chloride Injection | 国药准字H20233028 | 注射剂 | N/A | 粉体室：按头孢曲松（C₁₈H₁₈N₈O₇S₃）计1.0g；液体室：氯化钠注射液100ml∶0.9g | Chemical Drug | Approved | 2023/01/10 | Domestic | |
Ceftriaxone Sodium for Injection and Sodium Chloride Injection | 国药准字H20223648 | 注射剂 | N/A | 粉体室：按头孢曲松（C₁₈H₁₈N₈O₇S₃）计1.0g；液体室：氯化钠注射液 100ml：0.9g | Chemical Drug | Approved | 2022/09/14 | Domestic | |
Ceftriaxone Sodium for Injection and Sodium Chloride Injection | 国药准字H20233029 | 注射剂 | N/A | 粉体室：按头孢曲松（C₁₈H₁₈N₈O₇S₃）计2.0g；液体室：氯化钠注射液100ml∶0.9g | Chemical Drug | Approved | 2023/01/10 | Domestic | |
Ceftriaxone Sodium for Injection | 国药准字H20056797 | 注射剂(粉针剂) | N/A | 按C18H18N8O7S3计0.75g | Chemical Drug | Approved | 2015/12/21 | Domestic | |
Ceftriaxone Sodium for Injection | 国药准字H20067960 | N/A | N/A | 0.5g（按C18H16N8Na2O7S3计算） | Chemical Drug | Approved | 2006/11/09 | Domestic | |
Ceftriaxone Sodium for Injection | 国药准字H20053004 | N/A | N/A | 1.5g(按C18H18N8O7S3计算) | Chemical Drug | Approved | 2005/01/04 | Domestic | |
Ceftriaxone Sodium for Injection | 国药准字H10920097 | 注射剂 | 罗塞秦 | 0.5g( 按C18H18N8O7S3计) | Chemical Drug | Approved | 2020/06/10 | Domestic | |
Ceftriaxone Sodium for Injection | 国药准字H20044890 | 注射剂 | N/A | 4.0g(按C18H18N8O7S3计) | Chemical Drug | Approved | 2020/06/12 | Domestic | |
Ceftriaxone Sodium for Injection | 国药准字H46020652 | 注射剂 | N/A | 1.0g(按C₁₈H₁₈N₈O₇S₃计) | Chemical Drug | Approved | 2020/02/19 | Domestic | |
Ceftriaxone Sodium for Injection | 国药准字H20044041 | 注射剂 | N/A | 3.0g | Chemical Drug | Approved | 2019/07/02 | Domestic |
Australia Approved Products
Product Name | ARTG ID | Sponsor | Status | Reg. Date | Ingredient |
|---|---|---|---|---|---|
CEFTRIAXON ceftriaxone (as sodium) 2 g powder for injection vial | 283499 | MedTAS Pty Ltd | Active | 2017/12/08 | ceftriaxone sodium |
CEFTRIAXONE ACT ceftriaxone (as sodium) 2g powder for injection vial | 92400 | Juno Pharmaceuticals Pty Ltd | Active | 2003/01/28 | ceftriaxone sodium |
CEFTRIAXON ceftriaxone (as sodium) 1 g powder for injection vial | 283498 | MedTAS Pty Ltd | Active | 2017/12/08 | ceftriaxone sodium |
CFTRIAX ceftriaxone (as sodium) 1 g powder for injection vial | 283495 | Steriscience Pty Ltd | Active | 2017/12/08 | ceftriaxone sodium |
CEFTRIAXONE INJECTION ceftriaxone 500mg (as sodium) powder for injection vial | 104488 | Generic Health Pty Ltd | Active | 2004/07/22 | ceftriaxone sodium |
CEFTRIAXONE-AFT ceftriaxone (as sodium) 2g powder for injection vial | 185101 | AFT Pharmaceuticals Pty Ltd | Active | 2012/02/20 | ceftriaxone sodium |
CEFTRIXN ceftriaxone (as sodium) 1 g powder for injection vial | 283502 | MedTAS Pty Ltd | Active | 2017/12/08 | ceftriaxone sodium |
CEFTRIAXONE VIATRIS ceftriaxone (as sodium) 2 g powder for injection vial | 164917 | Active | 2012/01/20 | ceftriaxone sodium | |
CEFTRIAXONE VIATRIS ceftriaxone (as sodium) 1 g powder for injection vial | 164920 | Active | 2012/01/20 | ceftriaxone sodium | |
CEFTRIX ceftriaxone (as sodium) 1 g powder for injection vial | 283500 | MedTAS Pty Ltd | Active | 2017/12/08 | ceftriaxone sodium |